ORGO — Organogenesis Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Annual income statement for Organogenesis Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	468	451	433	482	564
Cost of Revenue
Gross Profit	354	346	327	366	427
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	397	429	421	483	519
Operating Profit	71	22.3	12.5	-1.28	44.7
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	63.8	20.3	10.4	-2.81	47
Provision for Income Taxes
Net Income After Taxes	94.9	15.5	4.95	0.861	37
Net Income Before Extraordinary Items
Net Income	94.9	15.5	4.95	0.861	37
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	94.9	15.5	4.95	-0.937	20
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.742	0.13	0.051	0.105	0.284